Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
NCT07551804Phase 2Recruiting
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of genotropin miniquick in growth hormone deficiency (GHD) (6 arms), sponsored by Xiamen Tebao Biological Engineering Co., Ltd. Primary endpoints: Adverse Events at Week 37, Serious Adverse Events at Week 37 and 36 more. Started Jun 2026; status: recruiting.
02
Drugs
genotropin miniquick
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT07551804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551804.